The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results

Khalid Al-Rasadi1,*, Khalid F. Alhabib2, Faisal Al-Allaf3, Khalid Al-Waili1, Ibrahim Al-Zakwani4, Ahmad AlSarrafa, Wael Almahmeed7, Nnsreen AlSayed8, Mohammad Alghamdi9, Mohammed A. Batais10, Turky H. Almigbal10, Fahad Alnouri11, Abdulhalim Kinsara12, Ashraf Hammouda13, Zuhier Awan14, Heba Kary15, Omer A. Elamin15, Fahad Zadjali16, Mohammed Al-Jarallah17, Abdullah Shehab18, Hani Sabbour17, Haitham Amin19 and Hani Altaradi2

1Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman; 2Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; 4Department of Pharmacology & Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman; 5Gulf Health Research, Muscat, Oman; 6Department of Medical Biochemistry, Ministry of Health, Kuwait City, Safat, Kuwait; 7Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE; 8Gulf Diabetes Specialist Center, Manama, Bahrain; 9National Guard Hospital, Riyadh, Saudi Arabia; 10Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 11Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia; 12King Saud bin Abdulaziz University for Health Sciences, College of Medicine, King Abdul Aziz Medical City, Jeddah, Saudi Arabia; 13Saud Al Babtain Cardiac Center, Dammam, Saudi Arabia; 14King Abdulaziz University, Jeddah, Saudi Arabia; 15King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia; 16Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman; 17Department of Medicine, Sabah Al-Ahmed Cardiac Center, Kuwait; 18Department of Internal Medicine, College of Medicine and Health Sciences, UAE; University, Al Ain, UAE; 19Bahrain Defense Force Hospital, Riffa, Bahrain

Abstract: Aim: To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolemia (FH) in the Gulf region.

Methods: Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with a previous clinical diagnosis of FH) and category 1 were stratified according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive FH will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics.

Results: The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of FH is 1/232.

Conclusion: The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multinational study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.

Keywords: Familial hypercholesterolemia, Middle East, registry, cardiovascular diseases, consanguinity, CHD.

1. INTRODUCTION

Familial hypercholesterolemia (FH) is a common genetic cause of premature coronary heart disease (CHD), due to lifelong elevated plasma low-density lipoprotein cholesterol (LDL-C) levels [1, 2]. The most common definitions used to diagnose FH are the Simon Broome Register criteria [2] and the Dutch Lipid Clinic Network (DLCN) criteria [3].

Both criteria are based on the presence of personal and first-degree family members of high cholesterol levels, premature CHD and tendon xanthomas. Another method to
identify FH is by DNA analysis of the 4 common FH genes: low-density lipoprotein receptor (LDLR), apolipoprotein B (ApoB), proprotein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein receptor adaptor protein (LDLRAP1) [4].

There are two forms of FH. For heterozygous FH (HeFH) the total cholesterol (TC) levels are around 8-15 mmol/L, patients typically develop CHD before 55 years of age and the prevalence in the general population varies between 1/200-500 [2]. This prevalence can be higher in subpopulations with founder effects [2]. For homozygous FH (HoFH), the TC levels are around 12-30 mmol/L, patients typically develop CHD very early in life and the prevalence can vary between 1/160,000-300,000 [2]. HeFH remains largely underdiagnosed with <5% of individuals being identified in most regions around the world [5]. Despite the high risk of CHD in patients with FH, many patients with FH remain untreated as shown by several studies [5-7]. There are a few reports on the clinical, molecular characteristics and management of FH in the Arabian Gulf region [8-13]. The exact prevalence of FH in the Arabian Gulf countries is unknown due to the lack of national FH registries [14].

The goals of this Gulf FH registry are to evaluate the prevalence, genetic characteristics, clinical management and cardiovascular disease (CVD) outcomes of FH in adult patients living in the Arabian Gulf region followed-up for 12 months. This manuscript describes the design and rationale of this multinational registry as well as presenting preliminary descriptive findings of phases I and II.

2. METHODS

2.1. Study Design and Population

Details of the study methodology are shown in Fig. (1). The registry is a mixture of both cross-sectional (phases 1, 2 and 3) and prospective (phase 4), multicentre, multi-national studies with a longitudinal clinical follow-up (phase 4). FH patients were recruited from out-patient (primary care, cardiology, endocrinology and lipid) clinics in 9 centres across 5 Arabian Gulf countries (Saudi Arabia, Oman, United Arab Emirates, Kuwait and Bahrain). The 4 phases of the registry are as follows:

2.2. Phase 1: Screening

Suspected FH patients from category 1 (new patients with no previous diagnosis of FH before the inclusion to this study) and category 2 (patients with previous clinical diagnosis of FH but with no genetic diagnosis before inclusion to this study) were recruited according to the lipid profile results and clinical data obtained through the hospital information systems over the previous 2-5 years and after satisfying the listed inclusion and exclusion criteria in the protocol. Patients who were on lipid-lowering treatments (LLTs), were included if the corrected LDL-C was ≥4.9 mmol/L (≥190 mg/dL) using an accepted correction formula [15, 16].

The final data was entered into the electronic case report form (eCRF), https://apex.oracle.com/pls/apex/f?p=111053:LOGIN_DESKTOP:113154011744149 and included patients from categories 1, 2 and 3 [patients with previous confirmed genetic diagnosis of FH before the inclusion to this study regardless of whether they have a baseline LDL-C above or below 4.9 mmol/L (190 mg/dL)]. Site investigators were encouraged to bring the patients to the clinics for full medical history and physical examination.

2.3. Phase 2: Stratification According to the DLCN Criteria

Patients from category 1 and 2 were stratified into possible FH (PoFH), probable FH (PrFH) and definitive FH (DFH) using the DLCN criteria [3].

2.4. Phase 3: Enrolment

Around 500 selected patients (300 from Saudi Arabia and 200 from other Arabian Gulf countries) with DFH and PrFH from categories 1 and 2 will undergo genetic testing for the 4 FH genes (LDLR, APOB, PCSK9 and LDLRAP1). The 500 patients will be mainly selected from the list of patients with definitive and probable FH based on the DLCN criteria. In case more patients are required, then those with possible FH and >4 points can be added.

Table 1. Sample size calculation.

| Country                  | National Population | Expected HeFH (1:500) | Sample Size as 10% of the Regional Sample |
|--------------------------|---------------------|-----------------------|------------------------------------------|
| Bahrain                  | 630,990             | 1,262                 | 126                                      |
| Kuwait                   | 1,281,712           | 2,563                 | 256                                      |
| Oman                    | 2,323,954           | 4,648                 | 465                                      |
| Saudi Arabia            | 20,708,462          | 41,417                | 4,142                                    |
| United Arab Emirates    | 950,368             | 1,901                 | 190                                      |
| Total                    | 25,895,486          | 51,791                | 5,179                                    |

Abbreviations: HeFH, heterozygous familial hypercholesterolemia.
2.5. Phase 4: Follow-up

The previous 500 patients from phase 3 with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate their clinical management and CVD outcomes (including unstable angina, myocardial infarction, coronary revascularization, stroke and CVD morbidity defined as hospitalisation for myocardial infarction, coronary revascularization, stroke, heart failure and arrhythmia). The data was entered into the 12 months follow-up eCRF. https://apex.oracle.com/pls/apex/f?p=111053:LOGIN_DESKTOP:113154011744149.

2.6. Inclusion and Exclusion Criteria

The inclusion criteria were age 18-70 years, Gulf nationals, LDL-C ≥4.9 mmol/L (≥190 mg/dL) and/or total cholesterol (TC) ≥7.5 mmol/L (≥290 mg/dL) not on LLTs or cor-

In an excel sheet collect the lipid results (TC, TG, LDL-C, HDL-C) over the previous 2-5 years through the LIS and HIS systems.

Phase 1: Screening with target of 5000 patients

Phase 1 screening eCRF

Exclude

include

For each patient start entering the data in the Phase 1 screening eCRF.

Phase 2: DLCN criteria stratification with target of 800 patients

The quality of the data from phase 1 (5000 patients) will be monitored and the patients will be stratified using the Dutch criteria into PFH, PrFH and DFH. The data will also be stratified into categories 1, 2 and 3

500 patients from category 1 and 2 with DFH and or PrFH.

100 patients from category 3 with DFH or PrFH.

Phase 3: Enrollment with target of 600 patients

From the 700 patients of phase 2, 500 patients will be enrolled from category 1 and 2 with DFH and or PrFH.

100 patients will also be enrolled from phase 2 from category 3 with DFH or PrFH.

The 500 patients will undergo blood collection, genetic testing and 12 months follow up.

The 100 patients will be followed after 12 months but they will not undergo genetic testing.

The samples for genetic testing will be transported by courier to Umm Al-Qura University at Makkah for the 300 Saudi patients and to Sultan Qaboos University in Oman for the 200 patients from the rest of the Gulf Arabian countries.

FH, familial hypercholesterolemia; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; LIS, laboratory information system; HIS, hospital information system; eCRF, electronic case report form; Dutch Lipid Clinic Network (DLCN) criteria; LLTs, lipid lowering treatments; PoFH, possible FH; PrFH, probable FH; DFH, definitive FH; SC, steering committee; CVD, cardiovascular disease.

Phase 4: One year follow up with target of 600 patients

The 600 patients from the phase 3 will be followed after 12 months for one visit from the date of enrollment.

The information regarding clinical management and CVD outcomes will be filled up by the investigators using the 12 months follow up eCRF.

1. Patient not on LLT and LDL-C <4.9 mmol/L (190 mg/dL) and/or TC <7.5 mmol/L (290 mg/dL).
2. TG >5 mmol/L (442 mg/dL).
3. Patient’s age < 18 or > 70 years.
4. Non-national.
5. Patient has one or more history of untreated hypothyroidism, proteinuria ≥1 g/L, obstructive liver disease, chronic renal failure, human immunodeficiency virus infection, on immunosuppressant or steroid or psychiatric medications.
6. LDL-C <4.9 mmol/L (190 mg/dL) after applying a correction factor for patients on LLT and LDL-C result between <4.9 mmol/L (190 mg/dL) and ≥2.6 mmol/L (100 mg/dL). This is only an optional criterion if it can be performed by the investigators.

In Fig. (1). Work flow for the Gulf FH Study. (A higher resolution / colour version of this figure is available in the electronic copy of the article.)
rected LDL-C ≥4.9 mmol/L (≥190 mg/dL) and category 3. The lipid results in this study are collected retrospectively, therefore, we cannot assure the fasting status although currently many laboratories in the region require collection of blood samples in the fasting status. The exclusion criteria were: triglyceride levels >5 mmol/L (442 mg/dL), history of untreated hypothyroidism, proteinuria ≥ 1 g/L, obstructive liver disease, chronic renal failure, human immunodeficiency virus infection (HIV) and use of immunosuppressants, steroids or psychiatric medications.

2.7. Sample Size

The sample size was derived from a 10% proportional sample of expected HeFH in each of the 5 Arabian participating countries as outlined in Table 1 based on a prevalence of expected HeFH of 1/500 [2].

2.8. Blood Samples and Genetic Testing Protocol

Two EDTA tubes will be collected from the selected 500 patients in phase 3 through the participating centres. The EDTA tubes will be shipped to Core Genetic laboratory centres in Saudi Arabia (Umm Al-Qura University, Makkah) and Oman (College of Medicine & Health Sciences, Sultan Qaboos University, Muscat). The EDTA tubes will be processed for DNA extraction and analysis of the 4 known genes LDLR, APOB, PCSK9 and LDLRAP1 using Ion PGM NGS platform in Saudi Arabia and Ion torrent NGS platform (Thermo Fisher Scientific, USA) in Oman. Target will cover all the exons (including the exon-intron boundaries), and 5’ and 3’ untranslated regions of the four FH-related genes (LDLR, APOB, PCSK9 and LDLRAP1). Ion AmpliSeq™ Designer tool will be used to custom design the assay primers. The human (Hg19) reference genome will be used to generate 200-bp amplicons.

The raw data acquired will be aligned to the human reference genome (Hg19) using the Torrent suite and recent version of the variant caller will be used. Standard stringency setting will be used for variant calling. Integrative Genomics Viewer (IGV) software [17] will be used to check for errors in variant calling. Variant annotation will be conducted using ANNOVAR tool [18] and filtering will cover exonic, splice sites and promoter regions. Synonym and intronic SNPs will be excluded. Allele frequency will be set to <10% using the Exact database and Greater Middle East Variome. The remaining variants will be analysed by comparing them with the Leiden Open Variation Database, the Familial Hypercholesterolemia Variants Database and scientific publications, for annotation purposes. Annotation in-silico will also be performed using tools that predict the functional effects of human SNPs: PolyPhen-2, SIFT and Mutation Taster. The genetic variants will be confirmed using direct sequencing. If no variants in the 4 major FH genes are found, then the DNA will be tested using Multiple Ligation-dependent Probe Amplification (MLPA) to detect large deletion or whole genome sequencing to detect new possible genes. For quality assurance and results verification, some samples will be exchanged between the 2 core laboratories with previously identified FH genetic mutations.

2.9. Statistical Analysis

Descriptive statistics (of phases 1, 3 and 4 findings) will be used to describe the data. For categorical variables, frequencies and percentages will be reported. Differences between groups will be analysed using Pearson’s χ² tests (or Fisher’s exact tests for cells <5). For continuous variables, mean and standard deviation will be used to present the data while analysis will be performed using Student’s t-tests. For non normally distributed continuous variables, median and interquartile range (IQR) will be used to summarize the data and the analysis will be performed by using Wilcoxon and Mann-Whitney tests. An a priori two-tailed level of significance will be set at 0.05. Statistical analyses will be conducted using STATA version 13.1 (STATA Corporation, College Station, TX, USA).

2.10. Confidentiality

Patients’ confidentiality will be maintained with no mention of their names or their national identification numbers. Each patient will be recognized in the registry by using an assigned unique registry number.

2.11. Ethical Considerations

The Gulf FH registry was approved by the local institutional ethics committees of each of the participating centres. Participants were also required to sign consent forms including an agreement for clinical and laboratory data sharing, blood collection for molecular testing and 1 year follow up for the collection of clinical and laboratory data.

3. RESULTS

Out of the total screened (n=34,366), 4,198 patients, forming the initial Gulf FH cohort, were entered into the eCRF (Phase 1) which also included patients from category 3 (n=184). The raw data from the eCRF was extracted into an Excel sheet and was filtered further based on the inclusion/exclusion criteria and the missing essential data for the DLCN criteria (Fig. 2). The final data consisted of 3,317 patients that were further classified according to the DLCN criteria (Phase 2) as shown in Table 3. The total number of patients with DFH, PrFH and PoFH were 203, 129 and 2,753, respectively (Table 2). A total of 232 patients were classified as unlikely FH. For Phase 3 and in only patients with no previous FH genetic diagnosis, around 500 patients will be selected from those shown in Table 3 (300 patients from Saudi Arabia and 200 patients from the rest of the 4 Arabian Gulf countries) to undergo FH genetic analysis, according to the genetic testing protocol highlighted above.

Considering the total number of patients screened, the prevalence of FH (based on both PrFH and DFH) was 0.43%, i.e. 1/232 (148/34,366).
Fig. (2). Schematic diagram of patient flow of Gulf FH study.
FH, familial hypercholesterolemia; TG, triglyceride; LDL-C, low density lipoprotein cholesterol. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

Table 2. Number of patients of FH per country stratified according to the DLCN criteria and including previous identified positive genetic mutation for FH.

| FH Type | KSA | Oman | UAE | Kuwait | Bahrain | Total |
|---------|-----|------|-----|--------|---------|-------|
| Unlikely FH | 191 | 4 | 9 | 13 | 15 | 232 |
| PoFH | 2119 | 280 | 105 | 164 | 85 | 2753 |
| PrFH | 71 | 44 | 4 | 8 | 2 | 129 |
| DFH | 104 | 87 | 9 | 2 | 1 | 203 |
| Total | 2485 | 415 | 127 | 187 | 103 | 3317 |

Abbreviations: FH, familial hypercholesterolemia; Dutch Lipid Clinic Network (DLCN) criteria; PoFH, possible FH; PrFH, probable FH; DFH, definitive FH.

Table 3. Number of patients of FH per country stratified according to DLCN criteria and excluding previous identified positive genetic mutation.

| FH Type | KSA | Oman | UAE | Kuwait | Bahrain | Total |
|---------|-----|------|-----|--------|---------|-------|
| Unlikely FH | 191 | 4 | 9 | 13 | 15 | 232 |
| PoFH | 2119 | 280 | 105 | 164 | 85 | 2753 |
| PrFH | 55 | 44 | 4 | 8 | 2 | 113 |
| DFH | 10 | 19 | 4 | 1 | 1 | 35 |
| Total | 2375 | 347 | 122 | 186 | 103 | 3133 |

Abbreviations: FH, familial hypercholesterolemia; Dutch Lipid Clinic Network (DLCN) criteria; PoFH, possible FH; PrFH, probable FH; DFH, definitive FH.
4. DISCUSSION

The Gulf FH registry is the first multi-national study of its kind in the Middle East region to determine the prevalence, genetic characteristics, clinical management and 12-month CVD outcomes of FH. The prevalence of FH in this study was 0.43% (1/232). However, this could be an overestimate as it only considered screened patients. Nevertheless, we believe this could also be a realistic estimate due to the high rate of consanguinity in the Gulf region [19]. In Norway, the prevalence of FH [20] is estimated to be around 1/300 and in the Copenhagen General Population Study [21] the prevalence of patients with PrFH or DFH combined using DLCN criteria is around 1/200.

Worldwide there are a number of existing FH registries that include patients based on either clinical or genetic diagnosis or both [22]. The Netherlands FH registry is considered the largest and >30,000 FH patients has been identified [22] but despite that, many FH patients are still underdiagnosed in many countries [5]. The situation in the Arabian Gulf countries is not different and FH remains underdiagnosed [14]. In the current study 203 and 129 are identified as DFH and PrFH, respectively. This could be due to the lack of local and regional registries, presence of only a few centres to perform genetic analysis, few lipid clinics in the region as well small number of educational programs on FH which could affect physician awareness about FH. A study conducted in Saudi Arabia to assess physician awareness, practice, and knowledge of FH in 4 tertiary hospitals showed that around 93% of the participants had poor knowledge of FH and only 7% had acceptable knowledge. Physicians' knowledge of FH in this study was assessed by 11 questions. A correct answer for each question was scored as 1 point, while an incorrect answer was given a score of 0. A mean knowledge score was computed by summing the correct answers to all 11 questions; possible total mean scores ranged from 0 to 11. The knowledge of FH was considered acceptable if the total score was >50% [23]. In addition, data from the Gulf RACE (1 and 2) and Gulf COAST registries [24-26] showed that patients in the Arabian Gulf region who present with an acute coronary syndrome (ACS) were 10 to 12 years younger than those in Western countries. In the sub-analysis from the Gulf COAST, in citizens from the Gulf region who were admitted with an ACS, the prevalence of “probable/definite” FH was 7 times higher than the estimated prevalence of FH in the general population, more than twice the one from a similar Swiss ACS cohort using the same DLCN criteria [13]. Moreover, in the same study, the incidence of atherosclerotic CVD (ASCVD) outcomes was higher in patients with probable/definite FH diagnosis after a 1-year follow-up [13].

Different methods can be used to screen for FH using clinical and/or genetic methods. Examples include universal screening of the general population or a more selective process, like screening patients from hospital information systems, patients admitted to acute coronary units with premature myocardial infarction or family cascade screening of patients with FH [27-33]. In the current study, we identified suspected FH cases through hospital laboratory and clinical data. The majority of patients were identified as possible FH according to the DLCN criteria and this could be due to missing important clinical information such as the presence of tendon xanthomas, family history of hypercholesterolaemia or premature CHD leading to mis-diagnosis and misclassification of patients with FH in this study. Nonetheless, this is considered as an initial initiative that will help to support subsequent national programs for FH screening in the Arabian Gulf region using other universal or selective screening methods including family cascade screening of patients with known FH.

Patients with FH are at high risk of developing ASCVD if not treated early and adequately [21]. Despite the presence of consensus clinical recommendations for the management of FH in the region [34-36] and the wide availability of statins and other LLTs, >50% of patients with FH in the Arabian Gulf region did not achieve their therapeutic LDL−C targets [13, 37]. Statins can reduce LDL−C up to 50% in HeFH and up to 25% in homozygous FH (HoFH) patients [38]. The combination of ezetimibe with a statin can decrease LDL−C by 60-70% in FH patients [39]. There are few lipoprotein apheresis centres for the treatment of HoFH and severe HeFH in the region. Lipoprotein apheresis can reduce the LDL−C levels by 50-70% [40]. Furthermore, there are few patients with HoFH on lomitapide which can reduce LDL−C up to 46% [40]. Recently, both alirocumab and evolocumab has became available in the region and are becoming widely used in combination with a statin and ezetimibe for the treatment of FH and severe ASCVD patients. Alirocumab can lower LDL−C levels by 60-68% [41] and evolocumab by 61-66% [42].

We believe that data analysis and future publications from this registry will enrich the existing literature and provide local health care authorities with an insight and recommendations regarding the challenges and quality improvement programs and policies for FH screening, diagnosis and management. One such policy implication is the development of premartial screening program and newborn screening for FH. Moreover, the detection of new FH patients in this registry will support the initiation of cascade genetic screening of family members, thus narrowing the gap of underdiagnosis and undertreatment of FH in the region.

Our study has some limitations which can be expected in any retrospective data mining. There are some missing data regarding the presence of tendon xanthomas, corneal arcus either in the patient or the first-degree family members. Also, there are missing data regarding first-degree family members with high LDL−C and premature CVD, which could affect the true estimation of FH prevalence in this population.

CONCLUSION

The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry aims to improve underdiagnosis and undertreatment of FH in the region.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by Gulf Registry of Prince Sultan Cardiac Centre Riyadh, Saudi Arabia with approval number: E16014.
HUMAN AND ANIMAL RIGHTS

No animals were used in this study. All reported experiments on humans were followed in accordance with the ethical standards of the committee responsible for human experimentation (institutional national), and with the Helsinki Declaration of 1975, as revised in 2008.

CONSENT FOR PUBLICATION

Written and informed consent has been obtained from all the patients.

FUNDING

The study was financially sponsored by Sanofi. The sponsor had no role in study design, data collection, analysis and interpretation; in the writing of the report and in the decision to submit the paper for publication.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

We thank our patients in the 5 Arabian Gulf countries, who consented to participate in this study; without them this study would not have been possible. The authors and investigators also thank Sanofi, Gulf Heart Association, Saud Heart Association, and Hani Altaradi for study coordination.

REFERENCES

[1] Goldstein JK, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scrivcr CR, Beaud, Sly WS, Valle D (Eds), The metabolic & molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001; pp. 2863-913.
[2] Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A Huge prevalence review. Ann J Epidemiol 2004; 160: 407-20.
[3] Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55-68.
[4] Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-803.
[5] Borge G, Nordestgaard B, Chapman J, Humphries SE. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013; 34: 3478-90.
[6] Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Huntet BA. Familial hypercholesterolemia: Current treatment and advances in management. Expert Rev Cardiovasc Ther 2008; 6: 567-81.
[7] Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223: 262-8.
[8] Shawar SM, Al-Drees MA, Ramadan AR, Ali NH, Alfadhlhi SM. The Arabic allele: A single base pair substitution activates a 10-base downstream cryptic splice acceptor site in exon 12 of LDLR and severely decreases LDLR expression in two unrelated Arab families with familial hypercholesterolemia. Atherosclerosis 2012; 220: 429-36.
[9] Al-Hinai AT, Al-Abri A, Al-Dhuhi H, et al. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. Angiology 2013; 64: 287-92.
[10] Al-Rasadi K, Al-Waili K, Al-Zidi WA, et al. Low-density lipoprotein receptor gene mutation analysis and structure-function correlations in an Omani Arab family with familial hypercholesterolemia. Angiology 2014; 65: 911-8.
[11] Al-Allaf FA, Athar M, Abduljaleel Z, et al. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene 2015; 562: 44-54.
[12] Alallaf F, H Nazar FA, Alinefae M, et al. The spectrum of familial hypercholesterolemia (FH) in Saudi Arabia: Prime time for patient FH registry. Open Cardiovasc Med J 2017; 11: 66-75.
[13] Al-Rasadi K, Al-Zakwani I, Alsheikh-Ali AA, et al. Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf. J Clin Lipidol 2018; 12: 685-92.
[14] Bamimore MA, Zaid A, Banerjee Y, et al. Familial hypercholesterolemia mutations in the Middle Eastern and North African region: A need for a national registry. J Clin Lipidol 2015; 9: 187-94.
[15] Ruel I, Aljenedel S, Sadri I1, de Varennes É, et al. Imputation of baseline LDL cholesterol concentration in patients with familial hypercholesterolemia on statins or ezetimibe. Clin Chem 2017; 64: 355-62.
[16] Haralambos K, Whatley SD, Edwards R, et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 2015; 240: 190-6.
[17] Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-6.
[18] Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
[19] el-Hazmi MA, al-Swailam AR, Warsy AS, et al. Consanguinity among the Saudi Arabian population. J Med Genet 1995; 32: 623-6.
[20] Heilberg A, Berg K. The inheritance of hyperlipoproteinemia with xanthomatosis. A study of 132 kindreds. Clin Genet 1976; 9: 203-33.
[21] Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97: 3565-74.
[22] Bellgard MI, Walker CE, Napier KR, et al. Design of the Familial Hypercholesterolaemia Australasia network registry: Creating opportunities for greater international collaboration. J Atheroscler Thromb 2017; 24: 1075-84.
[23] Batais MA, Almighbal TH, Bin Abdulhak AA, Altaradi HB, Al-Habib KF. Assessment of physicians’ awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PLoS One 2017; 12: e0183494.
[24] Zubaid M, Rashid WA, Almahmeed W, et al. Management and outcomes of Middle East patients admitted with acute coronary syndromes in the Gulf registry of acute coronary events (Gulf RACE). Acta Cardiol 2009; 64: 439-46.
[25] Alhabib KF, Sulaiman K, Al-Motarreb A, et al. Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the second Gulf registry of acute coronary events (Gulf RACE-2). Ann Saudi Med 2012; 32: 9-18.
[26] Zubaid M, Thani KB, Rashid W, et al. Design and rationale of Gulf locals with acute coronary syndrome events (Gulf coast) registry. Open Cardiovasc Med J 2014; 8: 88-93.
[27] Henneman L, McBride CM, Cornel MC, Duquette D, Qureshi N. Screening for Familial Hypercholesterolemia in children: What can we learn from adult screening programs? Healthcare 2015; 3: 1018-30.
[28] De Bocker G, Besseling J, Chapman J, et al. Prevalence and management of familial hypercholesterolemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European society of cardiology. Atherosclerosis 2015; 241: 169-75.
[29] Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial hypercholesterolemia in patients with acute coronary syndromes. Eur Heart J 2015; 36: 2438-45.
[30] Wonderling D, Uman-Seckhensena MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004; 4: 97-104.
[31] Shrerera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolemia using alternative diagnostic and identification strategies. Heart 2011; 97: 1175-81.
[32] Lázaro P, Pérez de Isla L, Watts GF. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol 2017; 11: 260-71.

[33] Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia. J Am Coll Cardiol 2018; 72: 662-80.

[34] Al Sayed N, Al Waili K, Alawadi F, et al. Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. Int J Cardiol 2016; 225: 268-83.

[35] Al Rasadi K, Almahmeed W, AlHabib KF, et al. Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis 2016; 252: 182-7.

[36] Al-Ashwal A, Alnouri F, Sabbour H, et al. Identification and treatment of patients with homozygous familial hypercholesterolaemia: Information and recommendations from a Middle East advisory panel. Curr Vasc Pharmacol 2015; 13: 759-70.

[37] Arafah M, Al-Hinai AT, Al Mahmeed W, et al. Centralized Middle East survey on the undertreatment of hypercholesterolemia: Results from the CEPHEUS study in Arabian Gulf countries. Angiology 2014; 65: 919-26.

[38] Nordestgaard BG, Chapman MJ, Humphries SE, et al. European atherosclerosis society consensus panel familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-90.

[39] Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010; 6: 1023-37.

[40] Cuchel M, Bruckert E, Ginsberg HN, et al. European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart J 2014; 35: 2146-57.

[41] Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36: 2996-3003.

[42] Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 331-40.